CLINICAL TRIALS

Please visit clinicaltrials.gov for detailed information about our ongoing clinical trials.

EPICENTRX CLINICAL TRIALS

 

Phase 3 Active Clinical Trials

Study: REPLATINUM: A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially with a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Carcinoma

Conditions: Small Cell Carcinoma
Interventions: Drug: RRx-001; Drug: Cisplatin/carboplatin

ClinicalTrials.gov Identifier: NCT03699956


 

Phase 1 and 2 Active Clinical Trials

Study: BETA PRIME: A Phase I, First in Human, Study to Evaluate the Safety and Tolerability of AdAPT-001 in Subjects With Refractory Solid Tumors. 3 + 3 dose escalation safety run-in (Part 1) followed by a dose expansion single-agent (Part 2).

Conditions: Solid Tumors, palpable / easily accessible for needle injection
Interventions:
Drug: AdAPT-001

ClinicalTrials.gov Identifier: NCT04673942